Dosage delivery form directly embedded with code

Abstract

The present disclosure provides a dosage delivery form 102 directly embedded with a code 104. The code 104 is printed using beams generated from a laser marking system. The code 104 is indicative of at least one or more parameters related to a traceability of the dosage delivery form 102, manufacturing attributes, or raw materials that are part of the dosage delivery form 102.

Description

DOSAGE DELIVERY FORM DIRECTLY EMBEDDED WITH CODETECHNICAL FIELD

[0001] The embodiments of the present disclosure generally relate to a field of pharmaceutical manufacturing and packaging technology, and specifically to integration of laser marking systems in a production of solid-state dosage forms, such as tablets and capsules, for embedding codes that facilitate traceability, identification, and verification of manufacturing attributes and raw materials.BACKGROUND

[0002] In pharmaceutical manufacturing, traditional printing methods such as inkbased printing, gravure roller printing, and offset roller printing have been widely used to apply codes, branding, and dosage information onto a dosage delivery form, for example tablets and capsules. Each method involves distinct processes and equipment but shares a common goal of marking dosage forms with necessary information. The ink-based printing is a widely used technique where liquid ink is applied directly onto a surface of the tablets or the capsules. The ink is typically applied using a printing head or a pad that transfers the ink onto the dosage delivery form. However, there is a risk of ink contaminating active ingredients, potentially affecting a safety and an efficacy of drug. Over time, the ink may bleed or migrate, leading to blurred or illegible markings. Inks used in pharmaceutical printing has to comply with stringent regulatory standards to ensure they do not interfere with the drug’s properties, adding to the complexity and cost.

[0003] Further, the gravure roller printing uses an engraved roller, known as a gravure cylinder, which is filled with ink. As the roller rotates, the gravure cylinder transfers ink impression onto a silicon / rubber roller and from this roller to the surface of the tablets or the capsules. The roller is etched with tiny cells that hold the ink, and the silicon / rubber roller is pressed against this roller holding the ink and the dosage forms are pressed against the silicon / rubber roller to receive the imprint. However, an initial cost of engraving gravure cylinders can be high, making it less economical for small production runs. The rollers may subject to wear over time, leading to a decrease in print quality and requiring frequent maintenance and replacement. Changes in design or information to be printed require new cylinders to be engraved, leading to delays and increased costs.

[0004] Furthermore, offset printing involves transferring ink from an inked image carrier (usually a plate) to a rubber blanket and then to the surface of the tablets or thecapsules. This indirect method may allow for high-quality and consistent printing across a large number of dosage forms. Moreover, the offset printing process is more complex and requires precise alignment to achieve high-quality prints, which may lead to increased setup time and potential errors. Residual ink on the blanket or the rollers may cause smudging or unintended transfer of the ink onto other dosage forms. The use of inks, especially solventbased inks, raises environmental concerns due to an emission of volatile organic compounds (VOCs) and a need for proper disposal of ink waste.

[0005] Therefore, there is, a need to address at least the above-mentioned drawbacks and any other shortcomings, or at the very least, provide a valuable alternative to the existing methods and systems.OBJECTS OF THE PRESENT DISCLOSURE

[0006] Some of the objects of the present disclosure, which at least one embodiment herein satisfies are listed herein below.

[0007] It is an object of the present disclosure to provide a dosage delivery form that is directly embedded with a code using laser marking technology, thereby enhancing traceability and identification of the dosage form throughout a manufacturing process and supply chain.

[0008] It is an object of the present disclosure to enable use of various laser marking systems, ensuring flexibility in selecting an optimal marking technology based on the material and production requirements.

[0009] It is an object of the present disclosure to accommodate laser marking systems with a wide range of wavelengths, allowing for precise and effective code embedding on different types of dosage forms.

[0010] Another object of the present disclosure is to ensure that a laser marking process can be applied to a variety of solid-state dosage forms, including tablets and capsules, providing versatility in pharmaceutical manufacturing.

[0011] Another object of the present disclosure is to facilitate printing of additional graphical or textual information on the dosage delivery form, such as branding, dosage instructions, and regulatory details, alongside the embedded code.

[0012] Yet another object of the present disclosure is to allow the embedded code to be in a form of Quick Response (QR) codes, barcodes, or other graphically represented codes, enhancing an ability to identify and track the dosage delivery form across different systems and platforms.SUMMARY

[0013] This section is provided to introduce certain objects and aspects of the present disclosure in a simplified form that are further described below in the detailed description. This summary is not intended to identify the key features or the scope of the claimed subject matter.

[0014] In an aspect, the present disclosure relates to a dosage delivery form directly embedded with a code. The code is printed using beams generated from a laser marking system. The code indicates at least one or more parameters related to a traceability of the dosage delivery form, manufacturing attributes, or raw materials that are part of the dosage delivery form.

[0015] In an embodiment, the laser marking system may be selected from any or a combination of Ultra-Violet (UV) laser marking systems, Carbon-di-oxide (CO2) laser marking systems, fiber laser marking systems, green laser marking systems, Yttrium Aluminum Garnet (YAG) laser marking systems, Master Oscillator Power Amplifier (MOPA) laser marking systems, and excimer laser marking systems.

[0016] In an embodiment, the laser marking system may have a predefined wavelength range, depending on a laser technology used.

[0017] In an embodiment, the dosage delivery form may be any or a combination of a tablet, a capsule, or a solid-state based dosage form.

[0018] In an embodiment, the laser marking system may facilitate printing of additional graphical or textual information on the dosage delivery form, including branding, dosage instructions, or regulatory information.

[0019] In an embodiment, the printing of the code may be performed at different stages of a production process, including a capsule filling stage, a capsule packaging stage, a tablet formation stage, a tablet coating stage, or a tablet packaging stage.

[0020] In an embodiment, the dosage delivery form may move on a conveyor system, and the laser marking system may print the code onto the dosage delivery form as required, with a possibility to orient the dosage delivery form for optimal code placement.

[0021] In an embodiment, the printing may be done either online during the production process or during the filling of the dosage form into its final packaging.

[0022] In an embodiment, the code may be any or a combination of a Quick Response (QR) code, a barcode, or any other graphically represented code that facilitates the identification and tracking of the dosage delivery form.BRIEF DESCRIPTION OF DRAWINGS

[0023] The accompanying drawings, which are incorporated herein, and constitute a part of this disclosure, illustrate exemplary embodiments of the disclosed methods and systems which like reference numerals refer to the same parts throughout the different drawings. Components in the drawings are not necessarily to scale, emphasis instead being placed upon clearly illustrating the principles of the present disclosure. Some drawings may indicate the components using block diagrams and may not represent the internal circuitry of each component. It will be appreciated by those skilled in the art that disclosure of such drawings includes the disclosure of electrical components, electronic components, or circuitry commonly used to implement such components.

[0024] FIGs. 1A and IB illustrate example representations (100A, 100B) depicting dosage delivery forms directly embedded with a code, in accordance with an embodiment of the present disclosure.

[0025] FIG. 2 illustrates a flow chart for implementing a method (200) for printing code on a dosage delivery form, in accordance with an embodiment of the present disclosure.

[0026] The foregoing shall be more apparent from the following more detailed description of the disclosure.DETAILED DESCRIPTION

[0027] In the following description, for the purposes of explanation, various specific details are set forth in order to provide a thorough understanding of embodiments of the present disclosure. It will be apparent, however, that embodiments of the present disclosure may be practiced without these specific details. Several features described hereafter can each be used independently of one another or with any combination of other features. An individual feature may not address all of the problems discussed above or might address only some of the problems discussed above. Some of the problems discussed above might not be fully addressed by any of the features described herein.

[0028] The ensuing description provides exemplary embodiments only and is not intended to limit the scope, applicability, or configuration of the disclosure. Rather, the ensuing description of the exemplary embodiments will provide those skilled in the art with an enabling description for implementing an exemplary embodiment. It should be understood that various changes may be made in the function and arrangement of elements without departing from the spirit and scope of the disclosure as set forth.

[0029] Specific details are given in the following description to provide a thorough understanding of the embodiments. However, it will be understood by one of ordinary skill in the art that the embodiments may be practiced without these specific details. For example, circuits, systems, networks, processes, and other components may be shown as components in block diagram form in order not to obscure the embodiments in unnecessary detail. In other instances, well-known circuits, processes, algorithms, structures, and techniques may be shown without unnecessary detail to avoid obscuring the embodiments.

[0030] Also, it is noted that individual embodiments may be described as a process that is depicted as a flowchart, a flow diagram, a data flow diagram, a structure diagram, or a block diagram. Although a flowchart may describe the operations as a sequential process, many of the operations can be performed in parallel or concurrently. In addition, the order of the operations may be re-arranged. A process is terminated when its operations are completed but could have additional steps not included in a figure. A process may correspond to a method, a function, a procedure, a subroutine, a subprogram, etc. When a process corresponds to a function, its termination can correspond to a return of the function to the calling function or the main function.

[0031] The word “exemplary” and / or “demonstrative” is used herein to mean serving as an example, instance, or illustration. For the avoidance of doubt, the subject matter disclosed herein is not limited by such examples. In addition, any aspect or design described herein as “exemplary” and / or “demonstrative” is not necessarily to be construed as preferred or advantageous over other aspects or designs, nor is it meant to preclude equivalent exemplary structures and techniques known to those of ordinary skill in the art. Furthermore, to the extent that the terms “includes,” “has,” “contains,” and other similar words are used in either the detailed description or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising” as an open transition word without precluding any additional or other elements.

[0032] Reference throughout this specification to “one embodiment” or “an embodiment” or “an instance” or “one instance” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present disclosure. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.

[0033] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the disclosure. As used herein, the singular forms “a”, “an”, and “the” are intended to include the plural forms as well, unless the context indicates otherwise. It will be further understood that the terms “comprises” and / or “comprising,” when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and / or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof. As used herein, the term “and / or” includes any and all combinations of one or more of the associated listed items.

[0034] Conventionally, printing methods such as ink-based printing, gravure roller printing, and offset roller printing have been widely used to apply codes, branding, and dosage information onto a dosage delivery form, for example tablets and capsules. Each method involves distinct processes and equipment but shares a common goal of marking dosage forms with necessary information. However, these printing methods may be more complex and require precise alignment to achieve high-quality prints, which may lead to increased setup time and potential errors. Residual ink on blanket or rollers of printing systems may cause smudging or unintended transfer of the ink onto other dosage forms. The use of inks, especially solvent-based inks, may raise environmental concerns due to an emission of volatile organic compounds (VOCs) and a need for proper disposal of ink waste. Therefore, there is, a need to address at least the above-mentioned drawbacks and any other shortcomings, or at the very least, provide a valuable alternative to the existing methods and systems.

[0035] The proposed dosage delivery form may be directly embedded with a code. The code may be printed using beams generated from a laser marking system. The code may be indicative of at least one or more parameters associated with any or a combination of traceability of the dosage delivery form, manufacturing attributes of the dosage delivery form, and raw materials that form part of the dosage form.

[0036] Various embodiments of the present disclosure will be explained in detail with reference to FIGs. 1A and IB.

[0037] Referring to FIGs. 1A and IB, a dosage delivery form 102 may be directly embedded with a code 104. The dosage delivery form 102 may be any or a combination of a tablet, a capsule, or a solid-state based dosage form. The code may be any or a combination of a Quick Response (QR) code, a barcode, an alphanumeric code, or any other graphically represented code that facilitates identification and tracking of the dosage delivery form 102.

[0038] In an embodiment, the code 104 may be printed using beams generated from a laser marking system. The laser marking system may be selected from any or a combination of Ultra-Violet (UV) laser marking systems, Carbon-di-oxide (CO2) laser marking systems, fiber laser marking systems, green laser marking systems, Yttrium Aluminum Garnet (Y AG) laser marking systems, Master Oscillator Power Amplifier (MOPA) laser marking systems, and excimer laser marking systems. In an embodiment, the laser marking system may have a predefined wavelength range, depending on a laser technology used. In an embodiment, the laser marking system may facilitate printing of additional graphical or textual information on the dosage delivery form 102, including branding, dosage instructions, or regulatory information.

[0039] Laser marking may be a precise and efficient method used to print the code 104 on the dosage delivery form 102, such as the tablets, the capsules, or other solid-state pharmaceutical forms. The laser marking process may involve generating beams that create permanent marks or codes 104 on a surface of the dosage delivery form 102, using the laser marking system. The laser marking system may generate a highly concentrated beam of light through a series of processes involving an excitation of atoms, an amplification of the light, and precise focusing of that light into a narrow, intense beam.

[0040] The laser marking system may include a laser medium, which may be a solid (like a crystal or glass), a liquid, or a gas. The laser medium may be selected based on a type of a laser which may be, for example, but not limited to, an UV laser, a CO2 laser, a fiber laser, or another type of laser, depending on a specific application and material properties of the dosage delivery form 102. The laser medium may have atoms or molecules that can be excited to higher energy levels.

[0041] To generate the laser beam, energy may be supplied to the laser medium through a pumping mechanism. The pumping mechanism may be selected from a group consisting of optical pumping, electrical discharge, and direct electrical pumping. This energy may be obtained from various sources, such as electrical currents, light from a flashlamp, or even another laser. The energy may excite the atoms or molecules in the laser medium, raising them to higher energy states. When the excited atoms or molecules return to their lower energy states, they release energy in a form of photons (particles of light). These photons may be emitted in all directions, but a few photons may travel in a direction of an optical cavity in the laser marking system.

[0042] As these photons pass through the laser medium, the photons may stimulate other excited atoms to emit more photons of a same wavelength and phase, which results inthe amplification of the light within the laser medium, leading to the generation of the highly concentrated light beam.

[0043] The laser medium may be placed between at least two mirrors in an optical resonator or cavity. One of these mirrors may be fully reflective, and the other may be partially reflective (allowing some light to escape). The mirrors may reflect the photons back and forth through the laser medium, causing more stimulated emission and further amplification of the light. As the light bounces between the mirrors, the light may become more and more coherent (i.e., the light waves may be in phase and have a uniform wavelength). This coherence may be a key characteristic of the laser light, making it different from ordinary light sources.

[0044] Eventually, the amplified light may become intense enough that a portion of the amplified light may escape through the partially reflective mirror. This escaping light may be the laser beam, which may be a highly concentrated, coherent, and collimated beam of light. After the laser beam is emitted, the laser beam may be typically passed through a series of lenses to focus it to a fine point through a focusing mechanism. This focusing mechanism may increase the beam's intensity even further, allowing it to mark, engrave, or cut the dosage delivery form 102 with precision. The laser marking system may control the beam's power, focus, and movement to achieve a desired marking effect. This control may allow for precise creation of patterns, text, or codes 104 on various surfaces. The laser may alter a chemical structure of a material during creation of the patterns, the text, or the codes 104, resulting in a change in colour of the patterns, the text, or the codes 104 applied on the dosage delivery form 102.

[0045] In an embodiment, the dosage delivery form 102 may be typically moved under the laser beam using a conveyor system or a precise positioning mechanism. The conveyor system may control a position and an orientation of each dosage delivery forms 102 to ensure that the code 104 is printed in a correct location and with optimal clarity.

[0046] In an embodiment, the laser marking system may be programmed with a specific pattern or the code 104 that needs to be printed on the dosage delivery form 102. The laser marking system may move the laser beam in a controlled manner to trace the pattern or the code 104 onto the surface of the dosage delivery form 102. This process may include complex shapes, text, or graphical codes that are necessary for traceability, branding, or regulatory compliance.

[0047] The laser marking may be a non-contact process, which means that the laser beam does not physically touch the dosage delivery form 102, thereby reducing a risk ofcontamination or damage to the dosage delivery form 102. Further, the codes 104 produced by the laser marking may be permanent and resistant to wear, making them ideal for ensuring traceability throughout the lifecycle of the dosage delivery form 102. The high contrast of the marks or the codes 104 may ensure that they are easily readable by scanners or human inspectors. The laser marking may meet regulatory requirements by ensuring that essential information is indelibly printed on each dosage delivery form 102. Furthermore, the laser marking system may be easily reprogrammed to print different codes on different batches, allowing for flexibility in production.

[0048] In an embodiment, the code 104 may indicate at least one or more parameters related to a traceability of the dosage delivery form 102, manufacturing attributes, or raw materials that are part of the dosage delivery form 102. The one or more parameters related to the traceability of the dosage delivery form 102 may include, but not limited to, a batch number, a manufacturing date, an expiration date, a lot number, a serial number, and the like.

[0049] The batch number may be a unique identifier assigned to a specific batch of dosage delivery forms 102, allowing for tracking throughout a manufacturing process and in case of recalls. The manufacturing date may be the date when the dosage delivery form was produced, which helps in monitoring a shelf life and identifying production timelines. The lot number may be a specific code that identifies a lot, which may consist of multiple batches. It may be useful for tracking in supply chain management. The serial number may be a unique number assigned to individual dosage units, enabling precise tracking and authentication.

[0050] The manufacturing attributes may include, but not limited to, manufacturing facility identification, regulatory compliance information, quality control data, packaging information, distribution information, recall information, and the like. The manufacturing facility identification may be a code or an identifier that represents a location or a facility where the dosage delivery form was manufactured. The regulatory compliance information may include details indicating adherence to specific regulations or standards, such as Food and Drug Administration (FDA) approval numbers or other certifications. The quality control data may include information related to quality checks and inspections carried out during the manufacturing process, including test results. The packaging information may include details regarding the packaging process, including a type of packaging used, a packaging date, and any specific conditions or instructions for handling. The distribution information may include data regarding a distribution chain, including a tracking of dosage delivery forms 102 through various distributors to a final point of sale. The recall information may include codes or data that may be used to identify products that need to be recalled in case of a defect or safetyissue. The raw materials that are part of the dosage delivery form 102 may include a raw material source including information about an origin of the raw materials used in the dosage delivery form 102, ensuring transparency and accountability in the supply chain. These parameters may ensure integrity, safety, and reliability of the dosage delivery forms 102 throughout their lifecycle, from production to end-use.

[0051] In an embodiment, the printing of the code 104 may be performed at different stages of a production process, including a capsule fdling stage, a capsule packaging stage, a tablet formation stage, a tablet coating stage, or a tablet packaging stage. The printing may be done at the capsule filling stage or the capsule packaging stage either in blisters or in foil. In the capsule filling stage, the capsules may be filled with Active Pharmaceutical Ingredients (APIs) and any other necessary excipients. The printing process may be integrated into this capsule filling stage, allowing the capsules to be marked with relevant information (e.g., a unique code, batch number, or branding) as they are being filled. This may ensure that the identification is directly applied to the capsules before they are packaged. After the capsules have been filled and sealed, the capsules are usually packaged for distribution. This packaging may take different forms, such as, the blisters and the foils. The capsules may be placed in individual cavities on a blister pack, usually made of plastic and sealed with a layer of aluminium foil or plastic film. Printing at this stage may involve marking information directly onto the blister pack, which may include the code, the expiration date, or any other required details. Alternatively, the capsules may also be packaged in foil pouches or strips. In this case, the printing may be done on the foil itself, providing necessary information for traceability and identification.

[0052] In an embodiment, the dosage delivery form 102 may be moved on a conveyor system, and the laser marking system may print the code 104 onto the dosage delivery form 102 as required, with a possibility to orient the dosage delivery form for optimal code placement. The conveyor system may be a moving belt or similar mechanism used to transport the dosage delivery form 102 (e.g., tablets or capsules) through various stages of the manufacturing process. As the dosage delivery forms 102 move along the conveyor system, they pass through different stations where specific tasks are performed.

[0053] As the dosage delivery forms 102 move along the conveyor system, the laser marking system may be programmed to print or engrave the code 104 onto each dosage delivery form 102. This may include the unique identifiers, the batch numbers, or any other relevant data needed for regulatory compliance and product identification. The position of the dosage forms may be oriented or adjusted as they move on the conveyor system. This mayensure that the laser may mark the code in an optimal location on each dosage delivery form 102. Proper orientation may be crucial for ensuring that the code 104 is placed correctly and is easily readable, ensuring that each dosage delivery form is marked uniformly, which is important for quality control, ensuring that the code 104 is printed on a flat or appropriate surface, maximizing a clarity and durability of the code 104. In an embodiment, the printing may be done either online during the production process or during the fdling of the dosage delivery form into its final packaging.

[0054] FIG. 2 illustrates a flow chart for implementing a method 200 for printing code on a dosage delivery form, in accordance with an embodiment of the present disclosure.

[0055] With reference to FIG. 2, at 202, the method 200 may include selecting a laser marking system from a group consisting of an UV laser marking system, a CO2 laser marking system, a fiber laser marking system, a green laser marking system, a YAG laser marking system, a MOPA laser marking system, and an excimer laser marking system. The laser marking system that is compatible with the material and surface of the dosage delivery form 102 may be selected.

[0056] At 204, the method 200 may include generating one or more laser beams using the selected laser marking system. The one or more laser beams may be generated through a series of processes involving an excitation of atoms, an amplification of the light, and precise focusing of that light into a narrow, intense beam, as illustrated in FIGs. 1A and IB. Each of the one or more laser beams may be configured with a specific wavelength, intensity, and pulse duration suitable for interacting with the surface of the dosage delivery form 102.

[0057] At 206, the method 200 may include creating a code indicative of at least one or more parameters associated with any or a combination of traceability of a dosage delivery form 102, manufacturing attributes of the dosage delivery form 102, and raw materials that form part of the dosage delivery form 102 using the one or more laser beams. The code may include a set of alphanumeric characters, symbols, or patterns that represent information related to the dosage delivery form 102.

[0058] At 208, the method 200 may include printing the code directly onto a surface of the dosage delivery form 102 using the selected laser marking system.

[0059] Therefore, by embedding the code 104 directly into the dosage delivery form 102, manufacturers and regulators may track the product from production to distribution, improving safety and accountability. Further, an ability to link the code 104 to specific manufacturing attributes and raw materials may ensure that the dosage delivery forms 102 meet regulatory standards and quality requirements. Thereby, providing clear and accessibleinformation through the embedded code 104 and enhancing consumer trust in the safety and efficacy of pharmaceutical products.

[0060] While considerable emphasis has been placed herein on the preferred embodiments, it will be appreciated that many embodiments can be made and that many changes can be made in the preferred embodiments without departing from the principles of the disclosure. These and other changes in the preferred embodiments of the disclosure will be apparent to those skilled in the art from the disclosure herein, whereby it is to be distinctly understood that the foregoing descriptive matter is to be implemented merely as illustrative of the disclosure and not as a limitation.ADVANTAGES OF THE PRESENT DISCLOSURE

[0061] The present disclosure provides a dosage delivery form that is directly embedded with a code using laser marking technology, thereby enhancing traceability and identification of the dosage delivery form throughout a manufacturing process and supply chain.

[0062] The present disclosure enables use of various laser marking systems, ensuring flexibility in selecting an optimal marking technology based on the material and production requirements.

[0063] The present disclosure accommodates laser marking systems with a wide range of wavelengths, allowing for precise and effective code embedding on different types of dosage forms.

[0064] The present disclosure ensures that a laser marking process may be applied to a variety of solid-state dosage forms, including tablets and capsules, providing versatility in pharmaceutical manufacturing.

[0065] The present disclosure facilitates printing of additional graphical or textual information on the dosage delivery form, such as branding, dosage instructions, and regulatory details, alongside the embedded code.

[0066] The present disclosure allows the embedded code to be in a form of Quick Response (QR) codes, barcodes, or other graphically represented codes, enhancing an ability to identify and track the dosage delivery form across different systems and platforms.

[0067] The present disclosure enables printing of the code either online during the production process or during the final packaging stage, ensuring seamless integration into existing manufacturing processes.

Claims

I Claim:

1. A dosage delivery form 102 directly embedded with a code 104, said code 104 is printed using beams generated from a laser marking system, and said code 104 being indicative of at least one or more parameters related to a traceability of the dosage delivery form 102, manufacturing attributes, or raw materials that are part of the dosage delivery form 102.

2. The dosage delivery form 102 as claimed in claim 1, wherein the laser marking system is selected from any or a combination of Ultra-Violet (UV) laser marking systems, Carbondi-oxide (CO2) laser marking systems, fiber laser marking systems, green laser marking systems, Yttrium Aluminum Garnet (YAG) laser marking systems, Master Oscillator Power Amplifier (MOPA) laser marking systems, and excimer laser marking systems.

3. The dosage delivery form 102 as claimed in claim 1, wherein the laser marking system has a predefined wavelength range, depending on a laser technology used.

4. The dosage delivery form 102 as claimed in claim 1, wherein the dosage delivery form 102 is any or a combination of a tablet, a capsule, or a solid-state based dosage form.

5. The dosage delivery form 102 as claimed in claim 1, wherein the laser marking system facilitates printing of additional graphical or textual information on the dosage delivery form 102.

6. The dosage delivery form 102 as claimed in claim 1, wherein the printing of the code 104 is performed at different stages of a production process, and wherein the different stages comprise any or a combination of a dosage delivery form filling stage, a dosage delivery form formation stage, or a dosage delivery form coating stage, or a dosage delivery form packaging stage.

7. The dosage delivery form 102 as claimed in claim 1, wherein the dosage delivery form 102 is moved on a conveyor system, such that the laser marking system prints the code 104 onto the dosage delivery form 102 as required.

8. The dosage delivery form 102 as claimed in claim 1, wherein the printing of the code 104 is performed in at least one of: online during the production process or during the filling of the dosage delivery form 102.

9. The dosage delivery form 102 as claimed in claim 1, wherein the code 104 is any or a combination of a Quick Response (QR) code, a barcode, or any other graphically represented code that facilitates identification and tracking of the dosage delivery form10. A method 200 for printing a code 104 on a dosage delivery form 102, the method comprising: selecting 202 a laser marking system from a group consisting of an Ultra- Violet (UV) laser marking system, a Carbon-di-oxide (CO2) laser marking system, a fiber laser marking system, a green laser marking system, an Yttrium AluminumGarnet (YAG) laser marking system, a Master Oscillator Power Amplifier (MOPA) laser marking system, and an excimer laser marking system; generating 204 one or more laser beams using the selected laser marking system; creating 206 a code indicative of at least one or more parameters associated with any or a combination of traceability of a dosage delivery form 102, manufacturing attributes of the dosage delivery form 102, and raw materials that form part of the dosage delivery form 102 using the one or more laser beams; and printing 208 the code directly onto a surface of the dosage delivery form 102 using the selected laser marking system.

Images